Noel Doheny - Epigenomics CEO of Epigenomics Inc.
EPGNF Stock | USD 0.50 0.00 0.00% |
CEO
Mr. Noel Doheny was Chief Executive Officer of Epigenomics Inc. of Epigenomics AG since May 2011. He has 30 years of experience in the field of diagnostics, with over 20 years in senior management. Prior to joining Epigenomics, he held positions as CEO of OpGen, Senior Vice President for the Molecular Diagnostics Division of Affymetrix Inc., Vice President of PreAnalytical Solutions and a member of the Executive Committee at QIAGEN as well as President and CEO of BioStar Inc. He has built several operating teams from the ground up, including the commercial teams to launch novel products at companies such as Ciba Corning, Biostar, and OpGen. Noel obtained degrees in Biology and Chemistry from West Virginia University and attended Georgetown University for postgraduate studies in Biochemistry prior to moving into industry. since 2011.
Tenure | 13 years |
Phone | 49 30 243 450 |
Web | https://www.epigenomics.com |
Epigenomics Management Efficiency
The company has return on total asset (ROA) of (0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3802) %, meaning that it generated substantial loss on money invested by shareholders. Epigenomics' management efficiency ratios could be used to measure how well Epigenomics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 5 records | CEO Age | ||
Timothy Damadian | Fonar | 60 | |
Ilan Danieli | Precipio | 52 | |
Scott Hutton | BiodesixInc | 52 | |
Keith Sullivan | Neuronetics | 66 | |
Harry Simeonidis | Intelligent Bio Solutions | 57 |
Management Performance
Return On Equity | -0.38 | |||
Return On Asset | -0.24 |
Epigenomics AG Leadership Team
Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gregory Hamilton, CEO Board | ||
Frederic Hilke, Investor Officer | ||
Jens Ravens, CFO Board | ||
Noel Doheny, CEO of Epigenomics Inc. | ||
Andrew Lukowiak, Pres Officer |
Epigenomics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Epigenomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.38 | |||
Return On Asset | -0.24 | |||
Operating Margin | (15.90) % | |||
Current Valuation | (9.71 M) | |||
Shares Outstanding | 4.09 M | |||
Shares Owned By Insiders | 35.00 % | |||
Shares Owned By Institutions | 4.86 % | |||
Price To Earning | (8.47) X | |||
Price To Book | 0.39 X | |||
Price To Sales | 10.64 X |
Pair Trading with Epigenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epigenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epigenomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Epigenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epigenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epigenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epigenomics AG to buy it.
The correlation of Epigenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epigenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epigenomics AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epigenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |